MSR20 Challenges in the Development of Economic Evaluations for Psychedelics in Treatment of Depression

Abstract

In recent years there have been significant advances in the use of psychedelic drugs (e.g., psilocybin) to treat depression, anxiety, addiction, and post-traumatic stress disorder. Interest in novel treatments for mental health conditions is fueled by the high added costs of these conditions, including direct medical costs and indirect costs such as productivity losses, as well as the relatively high “failure” rates of most standard treatments. In this presentation we discuss the main challenges faced when developing economic evaluations of psychedelics in the treatment of depression.